Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02586623 · ClinicalTrials.gov registry record · Phase 4
Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
A Phase 4 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 4
- Development phase
- 453
- Enrollment target
NCT02586623 is a Phase 4 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 453 participants.
The verdict
NCT02586623, a Phase 4 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 453 participants
- Enrollment target
Study Summary
To evaluate the time to treatment intervention in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Non-Diabetic Autonomic Neuropathy (NDAN) or Dopamine Beta Hydroxylase (DBH) Deficiency who have been previously stabilized with droxidopa therapy for symptoms of neurogenic orthostatic hypotension (NOH) (dizziness, light-headedness, or feelings that they are about to black out)
Interventions
- DRUG Placebo capsules
- DRUG Droxidopa capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 453 participants |
| Start Date | 2016-02-11 |
| Est. Completion | 2022-09-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02586623
The ClinicalTrials.gov registry entry for NCT02586623 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 453 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo capsules is the first listed.
NCT02586623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02586623 about?
NCT02586623 is a clinical study titled "Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension". To evaluate the time to treatment intervention in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Non-Diabetic Autonomic Neuropathy (NDAN) or Dopamine Beta Hydroxylase (DBH) Deficiency who have been previously stabilized with droxidopa therapy for...
What is the current status of trial NCT02586623?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 453 participants. The study started on 2016-02-11. Estimated completion is 2022-09-09.
What interventions are being tested in trial NCT02586623?
The interventions under investigation include: Placebo capsules (DRUG), Droxidopa capsules (DRUG).
Who is sponsoring clinical trial NCT02586623?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.